Levemir (insulin detemir rDNA origin) / Novo Nordisk - LARVOL DELTA

Experience with insulin detemir for type 2 diabetes in older people and people with comorbidities. (PubMed, Diabetes Metab Syndr) - "Detemir appears to be an effective and well-tolerated treatment for T2D in older people, and those with CVD, renal disease or liver disease."

Journal • Cardiovascular • Diabetes • Hepatology • Hypoglycemia • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Early vs. late initiation of long-acting basal insulin during IV insulin in pediatric diabetic ketoacidosis: a GRADE-assessed systematic review and meta-analysis. (PubMed, Eur J Pediatr) - " In pediatric DKA, starting long-acting basal insulin during IV insulin administration with an overlap of four hours or more speeds up metabolic resolution by about 3 to 5 h without raising the risk of hypoglycemia or hypokalemia. The effects on the duration of IV insulin and LOS are inconsistent. These findings support the use of early basal insulin as a safe transition strategy. Further multicenter pragmatic RCTs with standardized definitions for overlap are needed."

Clinical • Journal • Retrospective data • Review • Hypoglycemia • Metabolic Disorders • Pediatrics

Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review. (PubMed, J Pers Med) - " We systematically searched PubMed, Scopus, and Web of Science for studies published from the earliest available records to 18 August 2025 using the following Boolean search terms: "miRNA AND gliclazide", "miRNA AND glibenclamide", "miRNA AND gliquidone", "miRNA AND glimepiride", "mirRNA AND metformin", "miRNA AND pioglitazone", "miRNA AND rosiglitazone", "miRNA AND sitagliptin", "miRNA AND vildagliptin", "miRNA AND alogliptin", "miRNA and saxagliptin", "miRNA AND linagliptin", "miRNA AND liraglutide", "miRNA and dulaglutide", "miRNA AND semaglutide", "miRNA AND tirzepatide", "miRNA AND lixisenatide", "miRNA AND empagliflozin", "miRNA AND dapagliflozin", miRNA AND insulin glargine", "miRNA AND insulin detemir", "miRNA AND insulin degludec", "miRNA AND..."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Long-term antiepileptic therapy is often not required in dogs with insulin-induced hypoglycemic seizures: a multicenter retrospective study of 49 dogs. (PubMed, J Am Vet Med Assoc) - "Future studies are warranted to better identify patients at increased risk for long-term neurologic complications and to establish criteria for initiating AEDs. Additionally, research evaluating IIHS associated with other insulin preparations (eg, detemir, glargine) is needed."

Journal • Retrospective data • CNS Disorders • Epilepsy • Hypoglycemia

Systematic Review of the Cost-Effectiveness of Insulin Therapies in the Treatment of Type 2 Diabetes (ISPOR-EU 2025) - "Insulin icodec showed both cost savings (USD 479.96-974.01) and improved outcomes (0.04-0.08 QALYs) versus insulin degludec. Insulin glargine 100 was cost-effective compared to NPH insulin (ICERs USD 423.85-21,589.82) and dominant over insulin detemir... SR highlights the cost-effectiveness of various insulin therapies and offers valuable data for future pharmacoeconomic research. However, studies from Southeast Asia, including Vietnam, remain limited, indicating a need for further regional research."

Cost effectiveness • HEOR • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of Once-Weekly and Once-Daily Basal Insulins in Type 1 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis of Clinical Trials (ISPOR-EU 2025) - "In T1DM, once-weekly basal insulins appear to offer a slight advantage in reducing HbA1c at week 52. Although an increased risk of overall hypoglycemia was associated with icodec vs. degludec 100 and detemir at week 52, evidence suggests a comparable risk severe hypoglycemias between treatments."

Retrospective data • Review • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus

A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes (clinicaltrials.gov) - P1 | N=154 | Recruiting | Sponsor: Novo Nordisk A/S | Trial completion date: Jul 2025 ➔ May 2026 | Trial primary completion date: Jul 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Most individuals with type 2 diabetes on intensified insulin therapy do not require daytime basal insulin: results from a fasting glucose assessment in 531 patients (EASD 2025) - "Daytime basal insulins (degludec, detemir, glargine, and morning intermediate insulin) were discontinued. Only 6.6% of participants exhibited a clinically relevant increase in blood glucose without daytime basal insulin. These individuals received daytime basal insulin to stabilize fasting blood glucose levels. The majority remained stable without basal insulin until 14:00."

Clinical • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 2 Diabetes Mellitus

A Case of Heterozygous INS Gene Missense Variant in Neonatal Diabetes with Beta-Cell Autoantibodies: Experience in limited resources setting. (PubMed, Horm Res Paediatr) - "In settings where genetic testing is limited, cautious sulfonylurea use based on clinical algorithms is recommended. Regular monitoring of sulfonylurea response, pancreatic autoantibodies, and β-cell function is essential to guide therapy adjustments."

Journal • Diabetes • Infectious Disease • Metabolic Disorders • Pneumonia • Respiratory Diseases • KCNJ11

Diabetes in Pregnancy and Major New Advances in Diabetes Care Using Long and Ultra-Long Acting Insulins. (PubMed, Am J Obstet Gynecol) - "Insulin analogs, such as insulins glargine and detemir, are the most common basal insulins used in pregnancy at this time, but insulin degludec, which has advantages like prolonged duration of action in the non-pregnant population, was recently shown to be equally as effective as detemir in pregnancy. This would decrease basal injections from a minimum of 365 per year to 52 per year, potentially increasing adherence and improving glycemic control. This review will discuss the evidence for insulin degludec in pregnancy as well as discuss the potential benefits and drawbacks of once-weekly ultralong acting basal insulins in pregnancy."

Journal • Review • Diabetes • Gestational Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Cost-effectiveness of insulin icodec for the treatment of type 2 diabetes in Canada. (PubMed, J Med Econ) - "Outcomes were expressed as quality-adjusted life-years (QALYs) and cost-effectiveness as incremental cost utility ratios (ICUR [cost/QALY]).ResultsIn all analyses, insulin icodec dominated insulin degludec and insulin detemir. Compared to insulin glargine U100 and U300, insulin icodec was associated with ICURs of $17,876, $20,844, and $73,253; and $6,439, $8,623, and $45,433 in the IN, BIE, and BBIE populations, respectively.LimitationsLimitations of this economic evaluation include the lack of data for some treatments in certain NMAs, uncertainty regarding the use of the NMA results for a 40-year time horizon, heterogeneous sources of disutilities, and uncertainty regarding the HRQoL benefits of reduced injection frequency.ConclusionsInsulin icodec is a cost-effective treatment option for adult patients with T2D versus once daily basal insulin-analogues publicly reimbursed in Canada."

HEOR • Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Oral Anti Diabetic Agents in the Hospital (clinicaltrials.gov) - P4 | N=260 | Recruiting | Sponsor: Emory University | Trial completion date: Jul 2025 ➔ May 2026 | Trial primary completion date: Jul 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders

Cost-Effectiveness analysis of insulin therapies for patients with type 2 diabetes in Iran: a long-term analysis using the UKPDS model. (PubMed, J Diabetes Metab Disord) - "This study aims to evaluate the cost-effectiveness of four insulin therapies- neutral protamine Hagedorn (NPH) insulin, insulin glargine-100 (IGlar-100), insulin detemir (IDet), and insulin lispro protamine (ILPS) -used in the management of type 2 diabetes mellitus (T2DM) in Iran...The results of this study indicate that ILPS, compared to other evaluated insulins, is a cost-effective option, and thus the optimal choice in terms of efficiency at the population level. These findings provide critical insights for healthcare policymakers to guide decisions regarding diabetes treatment coverage and reimbursement strategies, ultimately improving patient access to cost-effective care."

HEOR • Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Role of Omnipod 5 Automated Insulin Infusion on Glucose Management in Patient with Anti-Insulin Antibodies (ENDO 2025) - "Previous management included metformin, Humalog 16 units before each meal, and Levemir 39 units at night. We believe this demonstrates successful management of the rare disorder of insulin autoimmune syndrome with the use of HumuLIN R U-200 insulin through Insulin Pump. Through multiple medication and treatment adjustments this patient's case shows an improvement over the course of treatment that can be used for future tests and trials."

Clinical • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Hypoglycemia • Immunology • Metabolic Disorders • Obstructive Sleep Apnea • Pain • Rare Diseases • Respiratory Diseases • Sleep Disorder • Type 2 Diabetes Mellitus

CF-IDEA (Cystic Fibrosis - Insulin Deficiency, Early Action): Randomised controlled trial of once-daily insulin detemir in patients with cystic fibrosis and early insulin deficiency (ANZCTR) - P2/3 | N=100 | Completed | Sponsor: Sydney Children's Hospital | Active, not recruiting ➔ Completed

Trial completion • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Real-World Evidence of Health Care Resource Use and Clinical Outcomes in People with Type 2 Diabetes and Impaired Renal Function Switching from First- to Second-Generation Basal Insulins in England (ADA 2025) - "To understand the health care resource use (HCRU) and clinical outcomes in patients with type 2 diabetes mellitus (T2DM) and decreased renal function (estimated glomerular filtration rate [eGFR]<60 ml/min/1.73 m2) who switched from a Gen1 BI to a Gen2 BI. In this retrospective, observational study in England, adults with T2DM who initiated treatment with a Gen1 BI (e.g., glargine 100 U/mL, detemir) and switched to a Gen2 BI (glargine 300 U/mL [Gla-300] or degludec [IDeg-100]) (index date) between 01/07/2014 and 31/03/2021 were analyzed using the Clinical Practice Research Datalink (CPRD) Aurum linked to Hospital Episode Statistics... This real-world study demonstrated that patients with T2DM and impaired renal function who switched to Gla-300 from Gen1 BI had lower HCRU among those treated with a second-generation BI."

Clinical • Clinical data • HEOR • Late-breaking abstract • Real-world • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus • GEN1

The impact of Insulin Degludec and Liraglutide Injection on clinical remission in patients with early - stage type 2 diabetes (ChiCTR) - P4 | N=600 | Recruiting | Sponsor: The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine; The First Affiliated Hospital of Guangxi University of Traditiona

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Healthcare utilization and costs in adults with type 2 diabetes treated with first or second-generation basal insulins in England. (PubMed, BMJ Open Diabetes Res Care) - "These findings suggest that Gla-300 may offer clinical and economic benefits by reducing hypoglycemia incidents and lowering healthcare costs compared with first-generation BI."

HEOR • Journal • Observational data • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparative Efficacy and Safety of Basal/Correctional Vs Basal/Bolus/Correctional Insulin Regimens in Medical Intensive Care Unit Patients Receiving Continuous Enteral Nutrition. (PubMed, Ann Pharmacother) - "Among ICU patients requiring ≥20 units of insulin detemir daily while receiving CEN, basal/correctional and basal/bolus/correctional insulin regimens appear to offer similar glycemic control, but basal/bolus/correctional regimens may improve glycemic control in patients requiring ≥60 units of insulin daily."

Journal • Critical care • Diabetes • Hypoglycemia

Insulin for early glycaemic abnormality in children with cystic fibrosis without cystic fibrosis-related diabetes (CF-IDEA): a randomised controlled trial. (PubMed, Lancet Child Adolesc Health) - P3 | "Insulin treatment did not improve weight or lung function when given to children and adolescents with cystic fibrosis and early glycaemic abnormalities. Insulin treatment should not be given to those who do not meet OGTT criteria for cystic fibrosis-related diabetes."

Clinical • Journal • CNS Disorders • Cystic Fibrosis • Diabetes • Epilepsy • Genetic Disorders • Immunology • Metabolic Disorders • Pediatrics • Pulmonary Disease • Respiratory Diseases • Severe Hypoglycemia

Hybrid closed loop in a residential setting: it takes a village but it is worth it (ESPE-ESE 2025) - "Despite being on basal bolus regimen with insulin aspart and detemir and wearing real-time continuous glucose monitoring, her glycaemic ranges were suboptimal (average sensor glucose 14.5mmol/L, GMI 9.6%, Time-in-Range 15%, Very High-Above-Range 57%, High-Above-Range 28%, HbA1c 61mmol/mol)...Our case suggests that HCL system together with a skilled diabetes MDT support offers promising benefits for residential use. Continued research is necessary to optimise the functionality of HCL system for this cohort."

Celiac Disease • Diabetes • Endocrine Disorders • Gastrointestinal Disorder • Hypoglycemia • Immunology • Metabolic Disorders • Rare Diseases • Type 1 Diabetes Mellitus

Localized Scleroderma in a Type 1 Diabetic Patient : A Case Report (ESPE-ESE 2025) - "Her medical history included an auto-immune hypothyroidism treated with 75 ug/day of levothyroxine...She was treated with insulin analogs: insulin detemir and aspart...The patient was started on methotrexate at 12.5 mg/week, and an insulin pump was proposed to obtain a better control of diabetes with reduced the number of injections. Conclusion The identification of localized scleroderma in a patient initially thought to have lipodystrophy highlights the importance of considering rare and atypical diagnoses in patients with diabetes as they can have a significant impact on diabetic control."

Case report • Clinical • Diabetes • Endocrine Disorders • Immunology • Lipodystrophy • Metabolic Disorders • Rare Diseases • Scleroderma • Systemic Sclerosis • Type 1 Diabetes Mellitus

Case of complete remission of diabetes mellitus type 1 (ESPE-ESE 2025) - "Treatment with lifestyle modification—diet to reduce weight, with basal insulin detemir and metformin—was recommended. The patient will continue to be under diabetologist care since her diagnosis of diabetes mellitus type 1 is established, and insulin treatment is expected to be necessary again once the honeymoon period passes. We present this case since it is not usual for obese adult women with prior GDM and a family history of type 2 diabetes mellitus to develop type 1 DM and even less often to develop complete remission shortly after delivery and pregnancy."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus in Teenagers – A Growing Concern for Armenia (ESPE-ESE 2025) - "Laboratory findings confirmed the diagnosis of T2DM: Fasting glucose: 28.7 mmol/L HbA1C: 11.0% C-peptide: 2.6 ng/mL Ketones: 3+ (indicating ketosis) Autoantibodies: Anti-GAD, IgG – 46.6 (>N) Anti-IA-2- 180.59 (>N) Anti-insulin, IgG – 10.13 (N) The patient’s treatment regimen included diet therapy (25 kcal/kg/day), insulin therapy (NovoRapid and Levemir), Metformin, and blood glucose monitoring 5-7 times per day. Early diagnosis and intervention, including lifestyle changes and pharmacological treatment, are essential to managing T2DM in teenagers and preventing long-term complications. Given the increasing prevalence of the condition in this age group, it is critical to recognize the early signs and implement appropriate strategies to address this growing public health issue."

Diabetes • Fatigue • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Neonatal diabetes mellitus in a boy with Wolfram-like syndrome. (ESPE-ESE 2025) - "He started on a low dose of insulin detemir with a glucose sensor and after a few days the treatment was changed to subcutaneous insulin via a pump at a dose of 0.4U/kg/day, allowing for his discharge... Patients with Wolfram-like syndrome can develop diabetes mellitus before the age of 6 months. Glucose levels should be evaluated regularly."

CNS Disorders • Diabetes • Epilepsy • Metabolic Disorders • Nephrology • Ocular Inflammation • Otorhinolaryngology